

## ASCORBIC ACID-BASED INHIBITORS OF $\alpha$ -AMYLASES

Andrew D. Abell\*,<sup>a</sup> Maureen J. Ratcliffe,<sup>a</sup> and Juliet Gerrard\*,<sup>b</sup>

<sup>a</sup>*Department of Chemistry, University of Canterbury, Christchurch, New Zealand*

<sup>b</sup>*New Zealand Institute of Crop & Food Research Ltd, Private Bag 4704, Christchurch, New Zealand*

Received 2 April 1998; accepted 28 May 1998

**Abstract:** A series of ascorbic acid and isoascorbic acid derivatives has been evaluated as inhibitors of malt, bacterial, fungal, pancreatic and salivary  $\alpha$ -amylases using a simple and quick assay procedure. The results demonstrate that the enediol moiety of ascorbic acid is essential for  $\alpha$ -amylase inhibition. Acylation of the primary and secondary alcohols, and the absolute configuration of the secondary alcohol, do not affect the potency of inhibition. © 1998 Elsevier Science Ltd. All rights reserved.

Starch is an important source of energy for most living organisms and is utilised in a series of degradation reactions catalysed by a variety of amylolytic enzymes of varying specificity. These include  $\alpha$ -amylases, which have attracted considerable attention in recent years.<sup>1</sup> Amylase inhibition is known to induce carbohydrate tolerance, satiety and weight loss, and it also prolongs gastric emptying.  $\alpha$ -Amylase inhibitors, therefore, have possible therapeutic potential in the treatment of obesity and non-insulin-dependent diabetes mellitus.<sup>2–4</sup> They are also of technological importance in the food industry when excessive  $\alpha$ -amylase activity causes problems during food processing.<sup>5–7</sup>

$\alpha$ -Amylase inhibitors generally fall into one of two categories: naturally occurring proteins, found in many plants, which are thought to act as a defense mechanism, e.g. against insect predators; and substrate analogues, particularly pseudooligosaccharides.<sup>8</sup> Proteinaceous  $\alpha$ -amylase inhibitors have been studied extensively and are now characterised in molecular detail providing further targets for synthetic mimics.<sup>9,10</sup>

Our attention was drawn to an obscure report<sup>11</sup> suggesting that ascorbic acid is an inhibitor of  $\alpha$ -amylase that appears to have been overlooked in subsequent literature. In this paper, we report the evaluation of a series of readily available ascorbic acid derivatives as inhibitors of  $\alpha$ -amylases using a simple and rapid screening procedure based on the Ceralpha method from Megazyme Australia.<sup>12,13</sup> This provides a rapid and convenient method for quantifying  $\alpha$ -amylase activity spectrophotometrically, based on liberation of *p*-nitrophenol from a modified oligosaccharide substrate. The assay is absolutely specific for  $\alpha$ -amylase and is linear, allowing adaptation of the method to provide detailed kinetic


information. The current study was undertaken to provide initial structure-activity information on this simple class of  $\alpha$ -amylase inhibitor.

**Table 1.** Inhibition of malt  $\alpha$ -amylase

| no.       | substituent                           |                |                |                | inhibition <sup>a</sup> |
|-----------|---------------------------------------|----------------|----------------|----------------|-------------------------|
|           | R <sup>6</sup>                        | R <sup>5</sup> | R <sup>3</sup> | R <sup>2</sup> |                         |
| <b>1a</b> | H                                     | H              | H              | H              | 95%                     |
| <b>1b</b> | H                                     | H              | H              | H              | 96%                     |
|           | (C5 epimer)                           |                |                |                |                         |
| <b>1c</b> | COMe                                  | COMe           | H              | H              | 89%                     |
| <b>1d</b> | CO(CH <sub>2</sub> ) <sub>14</sub> Me | H              | H              | H              | 90%                     |
| <b>1e</b> | H                                     | H              | Me             | Me             | 4%                      |
| <b>1f</b> | H                                     | H              | Me             | H              | 9%                      |
| <b>1g</b> | COMe                                  | COMe           | Me             | Me             | 0%                      |
| <b>1h</b> | COMe                                  | H              | Me             | Me             | 3%                      |
| <b>1i</b> | COEt                                  | H              | Me             | Me             | 7%                      |
| <b>1j</b> | CO(CH <sub>2</sub> ) <sub>2</sub> Me  | H              | Me             | Me             | 10%                     |
| <b>1k</b> | H                                     | H              | H              | H              | 4%                      |
|           | (2,3-dihydro)                         |                |                |                |                         |

| no.       | substituent    |                | inhibition <sup>a</sup> |
|-----------|----------------|----------------|-------------------------|
|           | R <sup>3</sup> | R <sup>2</sup> |                         |
| <b>2a</b> | H              | H              | 90%                     |
| <b>2b</b> | H              | H              | 93%                     |
|           | (C5 epimer)    |                |                         |
| <b>2e</b> | Me             | Me             | 2%                      |
| <b>2f</b> | Me             | H              | 29%                     |
| <b>2l</b> | COMe           | Me             | 9%                      |



<sup>a</sup> Malt  $\alpha$ -amylase was used for the initial screening process since it is inexpensive, readily available and stable at 4 °C. All inhibition values refer to a 5 mM solution of inhibitor and the values are expressed as a % relative to a control without inhibitor.

Two series of ascorbic acid derivatives were assayed for their ability to inhibit  $\alpha$ -amylases, one without acetal protection (compounds **1**, Table 1) and the other with an acetal at C5 and C6 (compounds **2**, Table 1). All the compounds were readily prepared from either ascorbic acid or isoascorbic acid using literature-based methods. Ascorbic acid **1a** was conveniently converted into the acetal **2a** on reaction with acetone and acetyl chloride.<sup>14</sup> Compound **2a** was a key intermediate to **2e**, **2f**, **2l** and indirectly, to **1e–1j**.<sup>15</sup> Ascorbic acid was also readily converted into **1c**,<sup>16</sup> **1d**<sup>17</sup> and **1k**<sup>18</sup> and isoascorbic acid **1b** gave **2b**.<sup>19</sup>

All of the most potent inhibitors (compounds **1a–1d**, **2a** and **2b**, Table 1) of malt  $\alpha$ -amylase possess a hydrogen at R<sup>2</sup> and R<sup>3</sup>. A range of substituents at R<sup>5</sup> and R<sup>6</sup> would appear to be tolerated, including H, acetal, COMe and an extended carbon chain at R<sup>6</sup> (compound **1d**).<sup>20</sup> The configuration at C5 would appear to be unimportant, with the isoascorbic acid examples **1b** and **2b** displaying similar

potency to the corresponding epimers, **1a** and **2a**. The introduction of methyl groups at both R<sup>2</sup> and R<sup>3</sup> results in a marked decrease in potency. This is also true when a single methyl group is introduced at R<sup>3</sup> (c.f. compounds **1f/1a** and **2f/2a**). Reduction of the C2-C3 double bond of **1a**, to give the 2,3-dihydro-derivative **1k**, also resulted in a marked decrease in inhibition. These combined results suggest that the enediol moiety of ascorbic acid is essential for  $\alpha$ -amylase inhibition. Finally, a similar pattern of inhibition was displayed against  $\alpha$ -amylases from malt, bacterial, fungal, pancreatic and salivary  $\alpha$ -amylases (see Tables 1 and 2). Kinetic studies are currently in progress to establish the mode of inhibition of  $\alpha$ -amylases by ascorbic acid and its derivatives.

**Table 2.** Inhibition of  $\alpha$ -amylases from other sources.

| no.       | $\alpha$ -amylase <sup>a</sup> |        |            |          |
|-----------|--------------------------------|--------|------------|----------|
|           | bacterial                      | fungal | pancreatic | salivary |
| <b>1b</b> | 99%                            | 98%    | 100%       | 100%     |
| <b>1c</b> | 92%                            | 91%    | 99%        |          |
| <b>1d</b> | 84%                            | 70%    | 88%        | 69%      |
| <b>2a</b> | 98%                            | 94%    | 99%        | 88%      |
| <b>2b</b> | 93%                            | 91%    | 99%        | 98%      |
| <b>2f</b> | 8%                             | 17%    |            | 0%       |

<sup>a</sup> All inhibition values refer to a 5 mM solution of inhibitor and the values are expressed as a % relative to a control without inhibitor. All enzymes were purchased from Sigma Chemical Company.

**Acknowledgment:** The work was supported in part by a grant from the New Zealand Marsden Fund. The authors also thank Neil McKeegan and Margy Gilpin for some preliminary studies.

## References and Notes

1. Soogard, M.; Abe, J.; Martin-Eauclaire, M.; Svensson, B. *Carbohydrate Polymers* **1993**, *21*, 137-146.
2. Tormo, M. A.; Ropero, F.; Nieto, M.; Martinez, I.; Campillo, J. E. *Phytotherapy Research* **1997**, *11*, 39-41.
3. Choudhury, A.; Maeda, K.; Murayama, R.; Dimagno, D. P. *Gastroenterology* **1996**, *111*, 1313-1320.
4. Takahashi, H. European Patent Application No. 92101636.6, **1992**.
5. Battacharya, M.; Corke, H. *Cereal Chemistry* **1996**, *73*, 721-728.

6. Macgregor, A. W. *J. Institute Brewing* **1996**, *102*, 97-102.
7. Klockiewicz-kaminska, E.; Warchalewska, J. R.; Piaseckakwiatkowska, D. *Nahrung* **1995**, *39*, 209-218.
8. Truscheit, E.; Frommer, W.; Junge, B.; Muller, L.; Schmidt, D. D.; Wingender, W. *Angew. Chem., Int. Ed. Engl.* **1981**, *20*, 744-761.
9. Oda, Y.; Matsunaga, T.; Fukuyama, K.; Miyazaki, T.; Morimoto, T. *Biochemistry* **1997**, *36*, 13503-13511.
10. Seffler, A. M.; Kozlowski, M. C.; Guo, T.; Bartlett, P. A. *J. Org. Chem.* **1997**, *62*, 93-102.
11. Palla, J.-C.; Verrier, J. *Ann. Technol. Agric.* **1974**, *23*, 151-159.
12. Sheehan, H.; McCleary, B. V. *Biotechnology Techniques* **1988**, *2*, 289-292.
13. McCleary, B. V.; Sheehan, H. *J. Cereal Sci.* **1987**, *6*, 237-251.
14. Jung, M. E.; Shaw, T. J. *J. Am. Chem. Soc.* **1980**, *102*, 6304-6311.
15. Nihro, Y.; Mijataka, H.; Sudo, T.; Matsumoto, M.; Satoh, T. *J. Med. Chem.* **1991**, *34*, 2152-2157.
16. Creighton, M.; Wenner, W.; Wuest, H. M. *J. Org. Chem.* **1948**, *13*, 613-615.
17. Cousins, R. C.; Seib, P. A.; Hosney, R. C.; Deyoe, C. W.; Liang, Y. T.; Lillard, Jr, D. W. *J. Am. Oil Chem. Soc.* **1977**, *54*, 308-312.
18. Andrews, G. C.; Crawford, T. C.; Bacon, B. E. *J. Org. Chem.* **1981**, *46*, 2976-2977.
19. Vekemans, J. A. J. M.; Boerekamp, J.; Godefroi, E. F.; Chittenden, G. J. F. *Recl. Trav. Chim. Pays-Bas* **1985**, *104*, 266-272.
20. The acyl substituents have been shown to be stable under the conditions of the assay.